Statera BioPharma Total Revenue

Statera BioPharma posts a total revenue of $3.7M as of September 2022. That compares with $240K in the prior-year period — up 1459.1% year over year. That is below the Healthcare sector average of $110B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Statera BioPharma's total revenue was $240K. The latest reading is $3.7M — a 1459.1% year-over-year increase (period ending September 2022). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a total revenue near $110B is typical. Statera BioPharma's $3.7M is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Total Revenue is one piece of Statera BioPharma's financial statement story. At $3.7M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for STAB's total revenue usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $110B), and (3) consistency with growth and profitability. This page covers the first two; Statera BioPharma's other metric pages and overview cover the third.